BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Akrimax Pharmaceuticals Announced the Launch of Suprenza (Phentermine Hcl) Orally Disintegrating Tablets (ODT) for the Management of Exogenous Obesity


5/24/2012 11:01:08 AM

CRANFORD, N.J., May 23, 2012 /PRNewswire/ -- Akrimax Pharmaceuticals announced the launch of Suprenza (phentermine HCl) orally disintegrating tablets (ODT) as a short-term adjunct in the management of exogeneous obesity. Obesity is a major concern in the United States and has been associated with increases in high blood pressure, diabetes, and other diseases. Suprenza is a sympathomimetic amine anorectic indicated for patients with an initial body mass index (BMI) of greater than or equal to 30kg/m squared or greater than or equal to 27kg/m squared in the presence of other risk factors (eg, controlled hypertension, diabetes, and hyperlipidemia).

Suprenza ODT is available from Akrimax in 15mg and 30mg dosage strengths. Dr. Keith Rotenberg (Corporate Vice President and Chief Scientific Officer) acknowledges findings from the US Centers for Disease Control and Prevention show that current statistics estimate over one third of the US population is overweight and another third of the population is obese. Dr. Rotenberg states that, "Suprenza provides physicians with a novel treatment alternative in the battle against obesity. Suprenza's unique formulation offers the patient the convenience of taking Suprenza with or without water and without regard to when the last meal was ingested." To assist patients with their weight loss, Akrimax has also created the Suprenza LEAN Program (Lifestyle, Exercise and Nutrition), which can be found at www.suprenza.com, along with further information on Suprenza.

Akrimax Pharmaceuticals is a privately-held, innovative specialty pharmaceutical company that acquires, develops and markets advanced ethical prescription medications. In addition to Suprenza ODT, the current company portfolio of products includes Tirosint ® (levothyroxine sodium), Primlev (oxycodone/acetaminophen), NitroMist® (nitroglycerin lingual aerosol), and Inderal® LA. More information on Akrimax and its products can be obtained at www.akrimax.com.

SOURCE Akrimax Pharmaceuticals



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES